ochnaflavone: from Lonicera japonica; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ochnaflavone : A biflavonoid with an ether linkage between the B-rings of the apigenin and luteolin subunits. It has been isolated from several members of the Ochnaceae plant family. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Ochnaceae | family | A plant family of the order THEALES, subclass Dilleniidae, class Magnoliopsida that have evergreen, alternate leaves.[MeSH] | Ochnaceae | A plant family of the order THEALES, subclass Dilleniidae, class Magnoliopsida that have evergreen, alternate leaves.[MeSH] |
| Lonicera | genus | A plant genus of the family CAPRIFOLIACEAE. Members contain iridoid glucosides.[MeSH] | Caprifoliaceae | A plant family of the order Dipsacales, subclass Asteridae, class Magnoliopsida.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5492110 |
| CHEBI ID | 194126 |
| SCHEMBL ID | 13829452 |
| MeSH ID | M0240262 |
| Synonym |
|---|
| ochnaflavone |
| 2-[4-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenoxy]phenyl]-5,7-dihydroxychromen-4-one |
| CHEBI:194126 |
| 50276-96-5 |
| AKOS016010710 |
| 4h-1-benzopyran-4-one, 2-(4-(5-(5,7-dihydroxy-4-oxo-4h-1-benzopyran-2-yl)-2-hydroxyphenoxy)phenyl)-5,7-dihydroxy- |
| 5b97q9uz5t , |
| unii-5b97q9uz5t |
| SCHEMBL13829452 |
| ochnaflavone7-o-beta-d-gluco-pyranoside |
| DTXSID70198281 |
| 2-{4-[5-(5,7-dihydroxy-4-oxo-4h-chromen-2-yl)-2-hydroxyphenoxy]phenyl}-5,7-dihydroxy-4h-chromen-4-one |
| Q17099497 |
| 4h-1-benzopyran-4-one, 2-[4-[5-(5,7-dihydroxy-4-oxo-4h-1-benzopyran-2-yl)-2-hydroxyphenoxy]phenyl]-5,7-dihydroxy- |
| 2-(4-(5-(5,7-bis(oxidanyl)-4-oxidanylidene-chromen-2-yl)-2-oxidanyl-phenoxy)phenyl)-5,7-bis(oxidanyl)chromen-4-one |
Ochnaflavone is a medicinal herbal product isolated from Lonicera japonica. It inhibits cyclooxygenase-2 (COX-2) dependent phases of prostaglandin D2 (PGD2) generation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ochnaflavone is a medicinal herbal product isolated from Lonicera japonica that inhibits cyclooxygenase-2 (COX-2) dependent phases of prostaglandin D2 (PGD2) generation in bone marrow-derived mast cells (BMMC) in a concentration-dependent manner with IC50 values of 0.6 microM. " | ( Naturally occurring biflavonoid, ochnaflavone, inhibits cyclooxygenases-2 and 5-lipoxygenase in mouse bone marrow-derived mast cells. Chang, HW; Kang, SS; Kim, HP; Lee, EK; Lee, SH; Moon, TC; Son, JK; Son, KH; Son, MJ, 2006) | 2.06 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| leukotriene antagonist | A drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| EC 3.1.1.4 (phospholipase A2) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4). |
| antiatherogenic agent | A cardiovascular drug that prevents atherogenesis, the accumulation of lipid-containing plaques on the innermost layers of the arteries. Compare with antiatherosclerotic agent. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| biflavonoid | A flavonoid oligomer that is obtained by the oxidative coupling of at least two units of aryl-substituted benzopyran rings or its substituted derivatives, resulting in the two ring systems being joined together by a single atom or bond. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| hydroxyflavone | Any flavone in which one or more ring hydrogens are replaced by hydroxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Group 10 secretory phospholipase A2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0410 | 0.1038 | 0.2000 | AID309539 |
| Phospholipase A2, membrane associated | Homo sapiens (human) | IC50 (µMol) | 3.5000 | 0.0030 | 1.0811 | 8.0000 | AID263929 |
| Cytosolic phospholipase A2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0005 | 1.0986 | 2.3000 | AID309540 |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | IC50 (µMol) | 100.0000 | 0.0620 | 0.1560 | 0.2500 | AID309537 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID251805 | Protective effect of compound on SNP-induced cell death in SH-SY5Y cells (concentration = 10 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID251810 | Protective effect of compound on SNP-induced cell death in SH-SY5Y cells (concentration = 0.4 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID251912 | Protective effect of compound on hydrogen peroxide-induced cell death in SH-SY5Y cells (concentration = 10 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID309539 | Inhibition of human cloned sPLA2-10 expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. |
| AID251924 | Protective effect of compound on hydrogen peroxide-induced cell death in SH-SY5Y cells (concentration = 0.4 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID1877612 | Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 56 | Cytotoxic effects of the biflavonoids isolated from Selaginella trichoclada on MCF-7 cells and its potential mechanism. |
| AID251904 | Protective effect of compound on hydrogen peroxide-induced cell death in SH-SY5Y cells (concentration = 2 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID251839 | Protective effect of compound on Ab25 35-induced cell death in SH-SY5Y cells (concentration = 0.2 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID263929 | Inhibition of sPLA2-2A in HEK293 cell | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Synthesis of phospholipase A2 inhibitory biflavonoids. |
| AID309537 | Inhibition of rat cloned sPLA2-1B expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. |
| AID309540 | Inhibition of human cloned cPLA2 expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. |
| AID309538 | Inhibition of human cloned sPLA2-5 expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. |
| AID251798 | Protective effect of compound on SNP-induced cell death in SH-SY5Y cells (concentration = 2 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID251831 | Protective effect of compound on Ab25 35-induced cell death in SH-SY5Y cells (concentration = 10 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| AID251824 | Protective effect of compound on Ab25 35-induced cell death in SH-SY5Y cells (concentration = 4 uM) | 2005 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15 | Neuroprotective effects of naturally occurring biflavonoids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||